LOADING

PADYNEX

Generic Name: Trastuzumab Emtansine
Originator’s name: Kadcyla®
Padynex is a HER2 antibody drug conjugate. The antibody portion is Trastuzumab, which is humanized anti-HER2 IgG1, and produced in the mammalian Chinese Hamster Ovary cells. The drug portion is DM1, which is a maytansine derivative that inhibits microtubules. These two portions are covalently connected by 4-[N-maleimidomethyl] cyclohexane-1-carboxylate (MCC), which is a stable thioether linker. Together MCC and DM1 are called Emtansine and are produced by chemical synthesis. Trastuzumab Emtansine binds to the HER2 receptor’s sub-domain IV and goes into the cell by receptormediated endocytosis. Lysosomes degrade Trastuzumab Emtansine and release
DM1. DM1 binds to tubulin in microtubules and inhibits microtubule function producing cell arrest and apoptosis. As well, similar to Trastuzumab, in vitro studies have shown that both HER2 receptor signalling inhibition and antibodydependent cytotoxicity are mediated by Trastuzumab Emtansine

 

INDICATION

  • Monotherapy for the treatment of HER2- positive, unresectable, locally advanced or metastatic breast cancer, in adult patients who have previously received trastuzumab and a taxane separately or in combination (initiated by a specialist)
  • Monotherapy for the treatment of HER2- positive, unresectable, locally advanced or metastatic breast cancer, in adult patients who have developed disease recurrence during or within 6 months of completing adjuvant therapy (initiated by a specialist)